KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Interest Expenses (2017 - 2025)

Arbutus Biopharma's Interest Expenses history spans 9 years, with the latest figure at $23000.0 for Q3 2025.

  • For Q3 2025, Interest Expenses fell 20.69% year-over-year to $23000.0; the TTM value through Sep 2025 reached $109000.0, down 27.81%, while the annual FY2024 figure was $137000.0, 70.15% down from the prior year.
  • Interest Expenses for Q3 2025 was $23000.0 at Arbutus Biopharma, down from $28000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $772000.0 in Q1 2021 and bottomed at $23000.0 in Q3 2025.
  • The 5-year median for Interest Expenses is $171000.0 (2023), against an average of $276736.8.
  • The largest annual shift saw Interest Expenses tumbled 89.28% in 2023 before it fell 17.65% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $560000.0 in 2021, then crashed by 44.82% to $309000.0 in 2022, then crashed by 85.76% to $44000.0 in 2023, then plummeted by 31.82% to $30000.0 in 2024, then decreased by 23.33% to $23000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Interest Expenses are $23000.0 (Q3 2025), $28000.0 (Q2 2025), and $28000.0 (Q1 2025).